Piper Jaffray Reiterates Overweight Rating and $11 PT on Vascular Biogenics (VBLT); Phase 2a Thyroid Cancer Drug Update
Tweet Send to a Friend
Piper Jaffray analyst Charles Duncan reiterates Overweight rating and $11 price target on Vascular Biogenics (NASDAQ: VBLT), as the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
